The STAR™ Tumor Ablation Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Concord, California, United States, 94520
- John Muir Medical Center
-
Escondido, California, United States, 92025
- Southern California Institute of Neurological Surgery
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
Stockton, California, United States, 95204
- St. Joseph's Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- Mori Bean and Brook Radiology
-
Lady Lake, Florida, United States, 32159
- Medical Imaging & Therapeutics
-
-
Illinois
-
Chicago, Illinois, United States
- VIR Chicago
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Health Sciences
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- University of Tennessee
-
-
Washington
-
Spokane, Washington, United States, 99204
- Providence Sacred Heart Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae (T1-L5) that will be treated with t-RFA using the STAR™ Tumor Ablation System.
- Have signed informed consent
Exclusion Criteria:
- Subjects under 18 years old
- Subjects with heart pacemakers, or other electronic device implants
- Subjects intended for t-RFA in vertebral body levels C1-7
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients receiving Targeted Radiofrequency Ablation (t-RFA)
|
Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain relief (Numerical Rating Pain Scale), post t-RFA
Time Frame: 1 month
|
measured by Numerical Rating Pain Scale (NRPS, 0-10 scale)
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain & Quality of Life Improvement (measured by the FACT G7 & Numerical Rating Pain Scale)
Time Frame: 1 week, 1 month, 3 month, 6 month, 12 month
|
measured by the FACT G7 & Numerical Rating Pain Scale
|
1 week, 1 month, 3 month, 6 month, 12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- DF-15-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Lesions in Vertebral Bodies
-
NCT02081053Terminated
-
NCT02225223TerminatedMetastatic Lesions in Vertebral Bodies
-
NCT01757717CompletedMetastatic or Recurrent Lesions in the Spine | Metastatic or Recurrent Lesions in the Pelvis
-
NCT00941213UnknownFractures of Vertebral Bodies
-
NCT00781924CompletedFocal Liver Lesions | Focal Lesions in the Abdomen
-
NCT02278744Active, not recruiting
-
NCT04569201UnknownEndoscopy in Intraventricular Lesions
-
NCT02701712Active, not recruitingSolid Tumors and Metastatic Lesions
-
NCT03561038WithdrawnComparing the Franseen and Fork-top Needles for EUS-guided Fine-needle Biopsy of Solid Mass Lesions.Solid Mass Lesions in GI Tract
Clinical Trials on STAR™ Tumor Ablation System
-
NCT02225223TerminatedMetastatic Lesions in Vertebral Bodies
-
NCT02081053Terminated
-
NCT04442113WithdrawnAtrial Fibrillation
-
NCT02189161CompletedAnal Intraepithelial Neoplasia (AIN) | High-grade Squamous Intraepithelial Lesions (HSIL)
-
NCT02729753Completed
-
NCT05826665RecruitingPersistent Atrial Fibrillation
-
NCT01061294Completed
-
NCT07017855Not yet recruitingStereotactic Radiation | Ventricular Tachycardia (VT) | Ventricular Tachycardia, Monomorphic | Cardioverter-Defibrillators, Implantable | Ventricular Tachycardia (V-Tach) | Stereotactic Body Radiation Therapy (SBRT) | Ventricular Tachycardia, Sustained | Stereotactic Techniques
-
NCT06431815Active, not recruitingParoxysmal Atrial Fibrillation
-
NCT07159048Not yet recruitingHepatocellular Carcinoma | Colorectal Cancer Liver Metastasis